The GeneXpert diagnostic testing technology from the US corporation Cepheid, and its parent company Danaher, has revolutionised rapid, accurate diagnosis of tuberculosis (TB) and other diseases, since entering the market in 2010. Yet, due to the high cost of the GeneXpert test cartridges, many countries are not able to scale up testing for all people who need lifesaving diagnosis and subsequent treatment.
With affordable generics likely years away, ViiV must make information public on supply of long-acting cabotegravir and global distribution plan to ensure access for people in high HIV burden low- and middle-income countries
2019 patent challenge by TB survivors, Nandita Venkatesan and Phumeza Tisile, was successful against J&J's secondary patent application for bedaquiline.
MSF statement at the Fourth meeting of the Intergovernmental Negotiating Body (INB) for a World Health Organization instrument on pandemic prevention, preparedness and response.
Ahead of the final hearing on a patent challenge by two TB survivors, MSF urges the Indian Patent Office to reject Johnson & Johnson’s secondary patent application so that other manufacturers may enter the supply chain with more ...
Findings that prompted WHO to update global DR-TB treatment guidelines now published in the New England Journal of Medicine, show that a much shorter treatment regimen for drug-resistant TB is safer and cured almost 90 percent of ...
MSF authors describe medical activities for people for snakebite, including the importance of offering antivenom free of charge, though costly for MSF.
The World Health Organization’s Global Tuberculosis Report 2022 highlights that still only one in three people with drug-resistant tuberculosis is getting treatment, and the treatment success rate for those who do receive treatment ...